SHANGHAI, June 18, 2024 /PRNewswire/ -- Over 40 guests, including 10 ambassadors to China, 8 consuls general and other senior diplomats from 26 countries, visited Fosun on 14 June. The delegation toured along the Grand Yuyuan. From the intangible cultural heritage of the Old City of Shanghai to the vibrant modernity of the Bund, they gained a deep appreciation for how Shanghai has preserved its cultural legacy while continuously promoting high-quality development. They also gained an in-depth understanding of Fosun's development over the past 30 years as a global enterprise rooted in China.
HONG KONG, May 23, 2024 /PRNewswire/ -- The 4th BEYOND International Technology Innovation Expo (BEYOND Expo 2024) commenced with a spectacular opening ceremony on 22 May at the Venetian Theatre in the Venetian Macao. At the opening ceremony, Guo Guangchang, Chairman of Fosun International, said that Fosun will steadfastly take innovation and globalization as the core drivers for its development in the next 30 years, pursuing stable revenue and profit growth. Guo Guangchang also pointed out that cancer can potentially be cured, and Fosun's vision is for humans to be able to live healthily and happily to 121 years old.
Fosun Pharma`s Self-developed Artemisinin Medicines Inject New Impetus to Malaria Prevention
SHANGHAI, April 26, 2024 /PRNewswire/ -- World Malaria Day is marked each year on April 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024 Accelerating the fight against malaria for a more equitable world. WHO stated that malaria not only continues to directly endanger health and cost lives, but it also perpetuates a vicious cycle of inequity. People living in the most vulnerable situations including pregnant women and children under 5 years of age continue to be disproportionately impacted.
CRANBURY, N.J., Aug. 8, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that Fosun Pharma, the licensee of Vyleesi in China, reported its first sale in the Hainan Province of China. Palatin also announced that their South Korean licensee, Kwangdong Pharmaceuticals, completed enrollment in its Phase 3 clinical trial evaluating the efficacy and safety of Vyleesi in premenopausal women with HSDD. Data from this trial is anticipated by year end with a potential regulatory submission in the first half of 2024.
Pharmaceutical manufacturing sites have been taking root in Africa over the past year and Fosun Pharma is looking to establish a significant production site on the continent as well.